ECSP21060962A - Composiciones farmacéuticas que comprenden meloxicam - Google Patents

Composiciones farmacéuticas que comprenden meloxicam

Info

Publication number
ECSP21060962A
ECSP21060962A ECSENADI202160962A ECDI202160962A ECSP21060962A EC SP21060962 A ECSP21060962 A EC SP21060962A EC SENADI202160962 A ECSENADI202160962 A EC SENADI202160962A EC DI202160962 A ECDI202160962 A EC DI202160962A EC SP21060962 A ECSP21060962 A EC SP21060962A
Authority
EC
Ecuador
Prior art keywords
meloxicam
migraine
rizatriptan
pain
administered
Prior art date
Application number
ECSENADI202160962A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of ECSP21060962A publication Critical patent/ECSP21060962A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Se describe en la presente composiciones que comprenden un NSAID como meloxicam y/o rizatriptan en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones pueden ser oralmente administradas, por ejemplo, para mejorar la biodisponibilidad o farmacocinéticas del NSAID para el tratamiento de dolor como migraña, artritis, y otras afecciones. También se describen aquí métodos para tratar el dolor, como migraña, que comprenden administrar meloxicam y rizatriptan a un ser humano que sufre de dolor, como migraña. Para la migraña, estos métodos pueden ser particularmente útiles cuando el meloxicam y el rizatriptan son administrados mientras el ser humano está sufriendo de un ataque agudo de dolor de migraña o aura de migraña. En algunas modalidades, la combinación de meloxicam y rizatriptan pueden ser administrados en una forma que resulta en una Tmax de meloxicam de 3 horas o menos.
ECSENADI202160962A 2019-02-06 2021-08-17 Composiciones farmacéuticas que comprenden meloxicam ECSP21060962A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US201962895933P 2019-09-04 2019-09-04
US201962895956P 2019-09-04 2019-09-04
US201962955905P 2019-12-31 2019-12-31

Publications (1)

Publication Number Publication Date
ECSP21060962A true ECSP21060962A (es) 2021-11-30

Family

ID=71947112

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202160962A ECSP21060962A (es) 2019-02-06 2021-08-17 Composiciones farmacéuticas que comprenden meloxicam

Country Status (17)

Country Link
EP (1) EP3920909A4 (es)
JP (3) JP7237386B2 (es)
KR (1) KR20210118880A (es)
CN (1) CN113423397A (es)
AU (2) AU2020218253B2 (es)
BR (1) BR112021015467A2 (es)
CA (2) CA3213549A1 (es)
CL (1) CL2021002070A1 (es)
CO (1) CO2021010380A2 (es)
CR (1) CR20210420A (es)
EC (1) ECSP21060962A (es)
IL (1) IL285389A (es)
MA (1) MA54904A (es)
MX (1) MX2021009435A (es)
PE (1) PE20212157A1 (es)
SG (1) SG11202107926XA (es)
WO (1) WO2020163620A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021414212A1 (en) * 2020-12-31 2023-07-20 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE284691T1 (de) * 1998-11-02 2005-01-15 Merck & Co Inc Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
WO2010132711A1 (en) * 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
WO2016131067A2 (en) * 2015-02-10 2016-08-18 Antecip Bioventures Ii Llc Pharmaceutical compositions comprising meloxicam
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
EP4008319A1 (en) * 2015-11-25 2022-06-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20220031944A (ko) * 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
CA3049229C (en) * 2017-01-04 2021-07-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
NZ758664A (en) * 2017-05-10 2022-08-26 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam

Also Published As

Publication number Publication date
PE20212157A1 (es) 2021-11-09
CR20210420A (es) 2021-12-22
CL2021002070A1 (es) 2022-04-01
SG11202107926XA (en) 2021-08-30
JP7237386B2 (ja) 2023-03-13
CA3128940C (en) 2023-11-07
AU2020218253B2 (en) 2023-02-23
JP2023062144A (ja) 2023-05-02
WO2020163620A1 (en) 2020-08-13
KR20210118880A (ko) 2021-10-01
AU2023202545A1 (en) 2023-05-18
JP2024026732A (ja) 2024-02-28
JP2022519670A (ja) 2022-03-24
MX2021009435A (es) 2021-09-10
EP3920909A4 (en) 2022-11-30
CA3213549A1 (en) 2020-08-13
AU2020218253A1 (en) 2021-08-12
BR112021015467A2 (pt) 2021-10-05
MA54904A (fr) 2021-12-15
IL285389A (en) 2021-09-30
EP3920909A1 (en) 2021-12-15
CO2021010380A2 (es) 2021-09-30
CA3128940A1 (en) 2020-08-13
JP7420990B2 (ja) 2024-01-23
CN113423397A (zh) 2021-09-21

Similar Documents

Publication Publication Date Title
CL2020003443A1 (es) Composiciones farmacéuticas que comprenden meloxicam
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
CO6341486A2 (es) Tratamiento y profilaxis de amiloidosis
EA200701195A1 (ru) Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
ECSP19014247A (es) Formas de dosificación para tratar y prevenir trastornos del sueño
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
ECSP21060962A (es) Composiciones farmacéuticas que comprenden meloxicam
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
MX2021002322A (es) Nuevos metodos.
BR112019009726A2 (pt) terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
BR112018068116A2 (pt) película transmucosal para administração de montelucaste
CL2020003010A1 (es) Moduladores de la expresión de apol1
BR112014030777A2 (pt) método e composição para aliviar sintomas de tumor
CO2021014024A2 (es) Métodos para tratar la distrofia muscular con casimersin
BR112019005224A2 (pt) forma de dosagem para alívio prolongado
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
MX2021003651A (es) Formulacion que comprende aceite ozonizado en el tratamiento de un tumor.